Figure 2.
The effect of the depletion of complement with CVF on the therapeutic activity of rituximab, 1F5, B1, and M15/8 in SCID mice. Groups of 4 to 5 SCID mice were injected with 2.5 × 106 Daudi or EHRB cells intravenously on day 0, and then treated with 100 μg 1F5, rituximab, or B1 (anti-CD20), M15/8 (anti-BCR), or PBS (cont) intravenously on day 7. In the complement-depleted groups (solid symbols), the animals were injected with 25 μg CVF intraperitoneally on days 7, 9, and 12 after tumor inoculation. Mice were culled when rear-leg paralysis was observed.
